Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Lucy CampbellFowzia IbrahimBirgit BarbiniAmanda SamarawickramaChloe OrkinJulie FoxLaura Jane WatersYvonne GilleeceShema TariqFrank A Postnull nullPublished in: HIV medicine (2021)
Switching from TDF/FTC/NNRTI to ABC/3TC/DTG improved the BMD of the lumbar spine and kidney function. These benefits need to be balanced against modest weight gain and the need for antiretroviral therapy substitutions in a proportion of participants.
Keyphrases
- antiretroviral therapy
- weight gain
- bone mineral density
- hiv infected patients
- postmenopausal women
- hiv infected
- human immunodeficiency virus
- birth weight
- body mass index
- hiv positive
- body composition
- hiv aids
- polycystic ovary syndrome
- pregnancy outcomes
- cervical cancer screening
- breast cancer risk
- insulin resistance
- metabolic syndrome
- physical activity
- south africa
- gestational age
- skeletal muscle
- men who have sex with men